A tumour-associated antigen is a target that is common in a tumour but can also be present in healthy tissue. A treatment aimed at it can affect both, and can also react with a different, look-alike target.
Many tumour-associated antigens come from unmutated proteins, so their usefulness depends on higher expression, an unusual expression pattern or accessibility in the cancer. A neoantigen, by contrast, arises from a tumour-specific sequence alteration. For an antibody or a chimeric antigen receptor, the question is accessible surface antigen on tumour and on healthy cells. For a peptide-directed T-cell receptor it is the particular peptide displayed by a particular HLA allele. RNA for the source gene establishes neither recognition surface, and a gene-expression result does not specify accessibility or peptide display.
Two hazards need different controls. On-target, off-tumour recognition means the receptor recognises its intended target in the wrong tissue. Off-target cross-reactivity means the receptor also recognises a different molecular target, so screening the intended antigen alone cannot rule it out. A published example of the second is an affinity-enhanced T-cell receptor directed at HLA-A*01-restricted MAGE-A3: in a clinical study the first two treated patients developed cardiogenic shock and died within days, no MAGE-A3 expression was detected in heart tissue at autopsy, and the T cells recognised an unrelated peptide from the striated-muscle protein titin (Linette et al., 2013; Cameron et al., 2013, who describe the preclinical analysis as having found no off-target concern). That illustrates the hazard for one engineered receptor and is not a toxicity rate for tumour-associated targets. Immune tolerance also shapes the available response to self antigens, and a stronger receptor does not remove the need to test healthy tissues and alternative targets.
A shared antigen can support a treatment intended for more than one person's cancer, with a trade-off between tumour coverage and healthy-tissue exposure; expression prevalence in a cohort is not a safe recognition threshold for a product. For vaccine-elicited peptide-specific T cells, a shared antigen offers another candidate when credible private targets are few, which is a coverage hypothesis, not demonstrated benefit. A peptide from a shared antigen and one from a neoantigen may depend on the same HLA allele, so changing the antigen does not restore a missing display route: Tran et al. (2016) documented escape after loss of the restricting HLA allele in one colorectal cancer patient. Antibodies and CARs have different recognition requirements, and epitope spreading is a separate widening of recognition that adding a shared antigen does not guarantee.
Shares HLA allele names and typing reports, Antigen, HLA (human leukocyte antigen) and MHC and the tag education-immunology-2026-11.
Shares HLA allele names and typing reports, HLA (human leukocyte antigen) and MHC.
Shares HLA allele names and typing reports, HLA (human leukocyte antigen) and MHC.
Shares HLA allele names and typing reports, HLA (human leukocyte antigen) and MHC, Neoantigen.
Shares Antigen, HLA (human leukocyte antigen) and MHC, Neoantigen.
Shares HLA allele names and typing reports, HLA (human leukocyte antigen) and MHC.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/